Clinical Takeaway
In this Phase 3 randomized controlled trial of 820 adults with chronic low back pain, VER-01, a full-spectrum Cannabis sativa extract, was evaluated over a 12-week blinded treatment period followed by up to one year of extended follow-up. The trial design included a randomized withdrawal phase, allowing researchers to assess both the durability of benefit and what happens when treatment stops. Results from this large, rigorously designed study provide some of the strongest clinical evidence to date on cannabis-based treatment for one of the most prevalent pain conditions globally.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based therapy in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and significant adverse effect profiles. The large sample size (n=820) and robust methodology combining double-blind treatment with extended open-label follow-up strengthen the validity of findings regarding both efficacy and long-term safety of full-spectrum cannabis extract, potentially offering clinicians a substantiated alternative for patients with inadequate response to or intolerance of conventional analgesics. If positive, these results could support the integration of standardized cannabis preparations into CLBP management protocols and establish a framework for future
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial of full-spectrum cannabis extract for chronic low back pain represents a meaningful addition to our evidence base, though clinicians should interpret the results within the context of several important limitations. The 12-week double-blind period and 6-month open-label extension provide valuable safety and efficacy data for a population where opioids and NSAIDs carry documented harms, yet the abstract does not specify primary outcome measures, effect sizes, or adverse event profiles that would allow for proper risk-benefit assessment. Cannabis preparations vary substantially in cannabinoid ratios, terpene profiles, and extraction methods, making it difficult to generalize findings from DKJ127 to other full-spectrum products patients may encounter in their communities. When counseling patients with CLBP who express interest in cannabis, referencing this emerging evidence alongside demonstrated efficacy of physical therapy, cognitive-behavioral approaches, and judicious pharmacotherapy helps contextualize cannabis as part of a comprehensive treatment strategy rather than a standalone solution.